Azilsartan medoxomil (Standard)
Azilsartan medoxomil (Standard) is the analytical standard of Azilsartan medoxomil (HY-14736). This product is intended for research and analytical applications. Azilsartan medoxomil (TAK 491), a prodrug form of Azilsartan (HY-14914), is an orally active angiotensin II receptor type 1 antagonist. Azilsartan medoxomil can be used for the study of essential hypertension.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98%
- CAS No.: 863031-21-4
- Formule: C30H24N4O8
- Masse moléculaire:568.53
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureté et documentation
-
Help & FAQs
-
HY-14736
Azilsartan medoxomilAngiotensin Receptor Antagonist -
HY-17512
LosartanAngiotensin II Receptor Antagonist -
HY-14914
AzilsartanAT1 Antagonist -
HY-B0202
IrbesartanAT1 Receptor Blocker -
HY-18204
ValsartanAngiotensin II Receptor Antagonist -
HY-17004
OlmesartanAT1R Antagonist -
HY-B0205
CandesartanAngiotensin II AT1-Receptor Blocker -
HY-13955
TelmisartanAngiotensin II Type 1 Receptor -
HY-18204A
Sacubitril/ValsartanARN Inhibitor -
HY-B0195
TranilastAnti-allergic Agent -
HY-15778
AVE 0991Ang-(1-7) Receptor Agonist -
HY-15834A
Eprosartan mesylateAngiotensin II Receptor Antagonist
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 863031-21-4
-
Masse moléculaire 568.53
-
Formule C30H24N4O8
-
SMILES
O=C(C1=C2C(N=C(OCC)N2CC3=CC=C(C4=CC=CC=C4C5=NC(ON5)=O)C=C3)=CC=C1)OCC6=C(C)OC(O6)=O
-
Synonyms
TAK-491 (Standard)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Kajiya T, Ho C, Wang J, Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens. 2011 Dec;29(12):2476-83. [Content Brief]
[2]. Kusumoto K, Igata H, Ojima M, Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. [Content Brief]
[3]. Perry CM. Azilsartan medoxomil: a review of its use in hypertension. Clin Drug Investig. 2012 Sep 1;32(9):621-39. [Content Brief]
[4]. Pierini D, Anderson KV. Azilsartan medoxomil/chlorthalidone: a new fixed-dose combination antihypertensive. Ann Pharmacother. 2013 May;47(5):694-703. [Content Brief]
[5]. French CJ, et al. The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques. J Cardiovasc Pharmacol. 2011 Aug;58(2):143-8. [Content Brief]
[6]. Ye Y, et al. Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size. Cardiovasc Drugs Ther. 2010 Apr;24(2):107-20. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Azilsartan medoxomil (Standard) Related Classifications
HY-14736R Related Classifications
Powered by Bioz